Can the cannabis industry turn growth into profits?

Thought Starters 阅读时间5分钟

Saxo Group

摘要:  Find out more about the current state of the marijuana industry, the trading opportunities it presents and how you can gain exposure to it with Saxo.

High growth sparks opportunities
The cannabis industry offers great growth opportunities over the next five years – but they come with great risk. 

The industry is bleeding on free cash flow generation, elevating the risks of refinancing its growth and operations. Recreational use is expected to become the main growth driver, but that comes with additional regulatory risks as cannabis was initially earmarked for medical use. The industry has also struggled in 2019 as market fundamentals have weakened, causing stocks to decline and bringing the possibility of bankruptcies sharply into view.

The key focus in 2020 will be whether the industry can show a path towards profitable growth.

All smoke and no fire?
As of January 2020, the publicly listed Cannabis industry, measured by the S&P/MX International Cannabis Index, had a combined market value $27.6bn, with the five largest companies being Canopy Growth, GW Pharmaceuticals, Cronos Group, Arena Pharmaceuticals and Aurora Cannabis. The index comprises 22 companies with a combined revenue in the last 12 months of $2.5bn – although this is largely concentrated among a few companies. 

The industry’s biggest issue is the lack of profitability amid the high growth – the index’s 12 month free cash flow shows a combined loss of $3.2bn. Consensus is expecting goodwill impairments to accelerate in Q4 as past acquisition values no longer add up with the weak market fundamentals seen in Canada during the second half. Some companies have goodwill-to-assets ratios of more than 50%, and a few more stand at around 20%, making the industry vulnerable from a balance-sheet perspective.

Bankruptcy concerns over some companies combined with large negative free cash flow means that the industry has a large, recurring refinancing issue. With the industry’s shares down 55% since September 2018, financing from traditional banks is drying up, which will leave shareholders to carry the burden of increasing the equity finance. The stock slide since also highlights the high-risk nature of the industry despite its fast growing revenues.

Recreational use to fan the flames
The cannabis industry’s historical growth rate has been high and this is expected to continue in 2020. Canada’s legal cannabis market is set to increase by 50% to around $1.7bn*, driven by more retail stores carrying marijuana products, including edibles, beverages and vaping devices. The biggest growth driver in the coming years is likely to be recreational use rather than medical use, but this will have to battle against the increased risk of consumer regulation.

Still, here at Saxo we expect growth rates to remain high for the years to come based on the projections from Bloomberg Intelligence and restructurings to accelerate the weeding out of weak companies in the industry. There will be more pain before the industry consolidates into bigger players with operational moats that can improve operating margins. Regulation has so far been a friend for the industry but over the years this could change as recreational marijuana use increases. Our view on the industry is that it will be volatile for years.

* According to Kenneth Shea, senior analyst (Food & Beverage) for Bloomberg Intelligence

Growth rolled up in volatility and risk
Since the cannabis index’s launch in September 2018 it has had annualised volatility of 45.6%, which is three times that of the S&P 500 at 15.1%. The correlation to the S&P 500 is only 0.11, showing that the industry is not driven by general macro factors but many idiosyncratic risk factors. It also highlights the appeal of Saxo’s new cannabis index futures, as the S&P 500 or any other equity index would be an inadequate hedging instrument.

The idiosyncratic risk factors facing the cannabis industry include the high debt levels of some companies and new regulations arising from an increase in recreational use. Also, goodwill impairment and very high equity valuations cause sharp declines in share prices during earnings releases, which helps to explain the high levels of volatility that make long-term investing difficult.

Trade Cannabis volatility with Saxo
To complement Saxo´s existing cannabis-related product offering, we recently launched S&P/MX International Cannabis Index Futures (SMJ). This means you can now get exposure to the major global cannabis index with a multiplier of 50. Not only will this enable you to hedge against potential losses and enhance your risk management, but more importantly it will also provide you with an efficient way to short the entire industry.

Source: Saxo Bank
You can trade a range of other cannabis-related instruments with Saxo, including equities, equity options, ETFs and single stock CFDs. By trading the latter, you´re able to go long or short, enabling you to capitalise on an individual cannabis stock’s volatility regardless of market conditions. And because you trade CFDs on leverage, your upside-potential is significantly increased – although the potential for loss is also greater. 

For reference, GW Pharmaceuticals (GWPH:xnas) makes up 13% of the total S&P/MX International Cannabis Index market cap, and you can trade it as a CFD via SaxoTraderGO with an initial margin rate of 20%.

Trading in financial instruments carries various risks. This also applies to futures and CFDs, where the total loss you may incur may exceed  the initial amount invested.
Get exposure to the cannabis industry
Open an account with Saxo to capitalise on trading opportunities in the high-growth marijuana industry.

盛宝银行集团旗下各实体仅提供纯粹的交易服务,网站上的分析报告仅供投资者阅读和/或引用,不作他用。盛宝银行提供的分析类资讯始终遵循以下条款和规则:(1)使用条款; (2)完整免责声明; (3)风险警示;(4)参与规则;(5)在盛宝银行集团相关网站上规范使用超链接访问盛宝资讯及研究栏目的相关条款,以及盛宝资讯及研究栏目和/或其具体资讯的注意事项。因此,所提供的内容仅作资讯之用。特别值得注意的是,盛宝银行集团实体无意提供任何建议,或提供让他人依赖的资讯或向他人授权资讯;这些资讯不构成业务招揽,也无意诱使他人认购、卖出或买入任何金融工具或产品。您所进行的所有交易或投资必须是依据您的自发性及自主作出的决定。为此,对于您因依赖盛宝资讯及研究栏目提供的资讯,或因根据盛宝资讯及研究栏目而作出的任何投资决定所蒙受的任何损失,盛宝银行集团实体概不承担责任。在盛宝银行集团实体开立的账户下的订单和交易才能真正生效。该盛宝银行集团实体是指在客户所在的司法管辖区经营,且客户在该实体开立及备存其交易账户的实体。盛宝资讯及研究栏目不包含(且不应被解读为包含)金融、投资、税收或交易意见,或由盛宝银行集团提供、推荐或授权的任何类型的投资建议,且不应被解读为对我们交易价格的记录,也不应被解读为向客户兜售认购、卖出或买入任何金融工具或产品。几乎所有内容都可视为投资研究,您必须注意和接受,这些内容并非旨在和依据专为推动投资研究独立化的法律要求而准备,并且在相关法律下不会被视为营销传播。

- 关于非独立投资研究的通知 (
- 完整免责声明 (
- 沪ICP备13028953号-1 (


所有交易都存在风险。阅读更多。为了帮助您了解所涉及的风险,我们整理了一系列关键信息文件 (KID),重点介绍了与每种产品有关的风险和回报。阅读等多


Apple 和 Apple 徽标是 Apple Inc. 在美国和其他国家和地区注册的商标。App Store 是 Apple Inc. 的服务标志。Google Play 和 Google Play 是 Google LLC 的商标。